Floatz logo
Floatz Rating
D31/100
Confidence
Indicative
v0.2
Sponsor
Pfizer
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
16High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06448364CT.gov
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
—Terminated———
NCT06285097CT.gov
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
—Terminated———
NCT05233436CT.gov
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
—Terminated———
NCT04152018CT.gov
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
—Terminated———
NCT02573259CT.gov
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urothelial Carcinoma

AssetSponsorPhaseRating
Sasanlimab (this asset)PfizerP1D · 31
CyclophosphamideBeijing BiotechP3BB
PembrolizumabSutro Biopharma, Inc.P3BB
Cis-Diamminedichloroplatinum IiNagoya UniversityP3BB
DurvalumabAlliance for Clinical Trials in OncologyP3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncP2/3BB
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, DimerEli Lilly and CompanyP3BB
DocetaxelNuCana plcP3BB
RetifanlimabIncyte CorporationP2BB

+42 more in the Urothelial Carcinoma cohort

Other indications for Sasanlimab

IndicationSponsorPhaseRating
Renal Cell Carcinoma—P2C · 39
Neoplasm—P2C · 39
Nonpapillary Renal Cell Carcinoma—P2C · 39

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Sasanlimab in Urothelial Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/sasanlimab-urothelial-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →